Invention Application
- Patent Title: ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS AS A PREDICTOR OF PATIENT RESPONSE TO INTERFERON-A THERAPY
-
Application No.: US15485420Application Date: 2017-04-12
-
Publication No.: US20170219585A1Publication Date: 2017-08-03
- Inventor: Larisa Geskin , Oleg E. Akilov
- Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Applicant Address: US PA Pittsburgh
- Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Current Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Current Assignee Address: US PA Pittsburgh
- Main IPC: G01N33/574
- IPC: G01N33/574 ; G01N33/50
Abstract:
The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
Information query
IPC分类:
